Assessment of the potential of growth factors for localized alveolar ridge augmentation: a systematic review Assessment of the potential of growth factors for localized alveolar ridge augmentation: a systematic review Abstract OBJECTIVE: To systematically assess the literature regarding the clinical, histological, and radiographic outcome of bone morphogenetic proteins (BMP-2, BMP-7), growth/differentiation factor-5 (GDF-5), platelet-derived growth factor (PDGF), and parathyroid hormone (PTH) for localized alveolar ridge augmentation. MATERIAL AND METHODS: Five separate Medline searches were performed in duplicate for human and animal studies, respectively. The primary outcome of the included studies was bone regeneration of localized alveolar ridge defects or craniofacial defects. RESULTS: In six human studies, BMP-2 affected local bone augmentation with increasing volume for higher doses. A majority (43 of 45) of animal studies using BMP-2 showed a positive effect in favour of the growth factor (GF).
Introduction
The ability to perform intraoral bone augmentation has expanded the treatment options in implant dentistry. Various methods have been described to augment bone prior to or in combination with implant installation: (a) grafting with autogenous bone from both intra-oral and extra-oral donor sites (Misch et al. 1992; Raghoebar et al.1996) , (b) guided bone regeneration (GBR), which allows spaces maintained by barrier membranes to be filled with bone (Dahlin et al. 1988; Kostopoulos & Karring 1994; Nyman & Lang 1994; Hämmerle et al. 1996) , (c) distraction osteogenesis, a gradual, controlled displacement of surgically created fractures (Ilizarov 1989a; Ilizarov 1989b), and (d) tissue engineering, which is a multidisciplinary field that aims to repair or even regenerate tissue and organs (Arosarena 2005) .
Among these methods, GBR is one of the best-documented techniques for intraoral bone augmentation (for a review see Hämmerle & Jung 2003) . However, GBR has different clinical limitations like the long treatment time, limited predictability for vertical bone augmentation (Simion et al. 1994) , risk of infection subsequent to membrane exposure (Chiapasco et al. 1999) , and technique sensitivity. In order to overcome some of these difficulties research has been driven towards the use of bioactive molecules to induce local bone formation (Urist 1965; Reddi et al. 1987) . A variety of growth factors including bone morphogenic proteins (BMPs), platelet-derived growth factor (PDGF), and peptides of the parathyroid hormone (PTH) have been tested for local bone regeneration.
BMPs belonging to the TGF-BB superfamily are most often named when it comes to growth factor enhanced bone healing. Among the more than 30 identified BMPs, only a small number (BMP-2, BMP-4, BMP-7, BMP-9) seem to have osteoinductive functions (Cheng et al. 2003) .
Several human clinical trials have been published using BMP-2 for bone regeneration (Boyne et al. 1997; Cochran et al. 2000; Jung et al. 2003) . These studies showed superior results using BMP-2 when compared to respective control groups. On the other hand, the selection of the carrier seems to play an important role in terms of bone regeneration with the use of growth factors (Sigurdsson et al. 1996; Wikesjo et al. 1998) . Research is demanded as collagen sponges used as carrier material lack mechanical stability (Barboza et al. 2000) .
Human cDNA BMP-7 (osteogenic protein-1; OP-1) was cloned in 1990. Recombinant human OP-1 (rhOP-1) was later developed and was shown to induce new bone formation comparable to natural bovine osteogenic protein (Sampath et al. 1992) . Based on favorable animal and clinical results concerning the osteogenic potential of rhBMP-7 (Friedlaender et al. 2001; Chen et al. 2002; Makino et al. 2005) , rhBMP-7 was commercialized (Stryker, Kalamazoo, MI, USA). In 2001, rhBMP-7 was approved in Australia and Europe for clinical use in non-unions. Compared to autografts, which necessitate a second surgical site, and therefore increase operating time, risk of morbidity, patient pain, and recovery, the use of BMP-7 was shown to be superior, especially in patients with known risk factors (Govender, et al. 2002; Kanayama, et al. 2006; Ronga, et al. 2006 ).
The growth/differentiation factors (GDFs) belong to the class of BMP signaling molecules.
Several mouse models exist with functional null mutations in GDFs leading to specific skeletal tissue phenotypes. These phenotypes allow studying the function of these GDFs (for an overview see Mikic 2004). It has been shown, that GDFs play an important role in the development and regeneration of tendon, cartilage, bone, and skin (Wolfman, et al. 1997; Storm & Kingsley 1999; Mikic, et al. 2002; Chhabra, et al. 2003) . Recent publications have been focused on the use of GDF-5 for local bone augmentation in the field of dentistry (Kuniyasu et al. 2003; Nakamura et al. 2003; Yoshimoto et al. 2006 ).
PDGF is a well-characterized tissue growth factor that has been used in various animal and human studies (Camelo et al. 2003; Nevins et al. 2003; Nevins et al. 2005; Park et al. 1998; Giannobile et al. 1996) . It was first introduced in dentistry in the field of periodontology and has shown to be mitogenic and chemotactic for periodontal ligament cells, with the additional effect of promoting regeneration of bone, ligament, and cement (Lynch et al. 1991; Lynch et al. 1989) . Recent publications have shown, that rhPDGF-BB combined with a deproteinized bovine block without placement of a barrier membrane, had the potential to regenerate significant amounts of new bone in severe mandibular ridge defects in an animal model (Simion et al. 2006) , as well as in patients (Simion et al. 2007 ). However, in contrast, another study showed, that the combination of rhPDGF-BB with a bone substitute material (deproteinized bovine bone mineral granules; DBBM) resulted in limited bone formation compared to DBBM alone (Lioubavina-Hack et al. 2005a ).
In addition to growth factors, the use of peptides of the parathyroid hormone (PTH) have also been investigated for modulating bone healing. PTH has been shown to have multiple anabolic effects on both cancellous and cortical bone (Rizzoli et al. 1992; Whitfield et al. 2000) . Presently, PTH is used for systemic treatment of osteoporosis. Clinical trials have shown this therapy to be effective in increasing bone density (Neer et al. 2001) . Few studies evaluated the use of PTH as an adjunctive factor for local bone augmentation (Skripitz et al. 2000; Jung et al. 2007a&b ).
To date, there is limited evidence for the application of growth factors for local bone augmentation in dentistry. The aim of the present review was therefore, to systematically assess the
Material and Methods

Search strategy
Five separate Medline (PubMed) searches were performed in duplicate for human and animal studies, respectively. The articles were published from 1966 up to September 2007 in the Dental literature. All searches were limited to the English and German languages. The following search terms were selected: "*bone morphogenic protein* (*bmp*)" (search 1 and 2 for bmp-2), "platelet derived growth factor* (*pdgf*)" (search 3 and 4), *parathyroid hormone* (*pth*)" (search 5 and 6), "osteogenic protein* (*op*)", or "*bone morphogenic protein* (*bmp*)" (search 7 and 8 for bmp-7, op-1), *growth/differentiation factor* (*gdf*)" (search 9 and 10). All these search terms were meshed with "*bone*", and "*regeneration*". 
Inclusion criteria
The applied inclusion criteria were different for preclinical and clinical studies. For the preclinical studies only controlled studies were included. The primary outcome of the experiments had to be local bone augmentation. At least 5 animals had to be included. A follow-up period was not defined. The reported treatment outcomes had to include at least 1 of the following parameters: clinical, radiographic, or histological effects of the growth factor (GF) or the control(s).
For the human studies, any prospective cohort was selected, which included at least 10 patients. The patients had to be followed for at least 3 months. The reported treatment outcomes were considered to be either clinical, radiographic, or histological. Again, the primary outcome of the studies had to be local bone augmentation.
Exclusion criteria
Studies not meeting all inclusion criteria were excluded from the review. Publications were also excluded if the primary outcome was not local bone augmentation. Studies dealing with the following topics were excluded: in vitro studies, studies using gene therapy, studies with focus on periodontal regeneration, studies reporting systemic treatment outcomes, craniofacial surgery for total or partial reconstruction of mandibles/maxillas, cleft lip and palate surgeries, distraction osteogenesis, or orthopedic surgeries.
Selection of studies
Titles derived from this broad search were independently screened by 2 authors (RJ, DT) based on the inclusion criteria. Disagreements were resolved by discussion. Cohen's Kappacoefficient was used as a measure of agreement between the 2 readers. Following this, abstracts of all titles agreed on by both authors were obtained, and screened for meeting the inclusion criteria. If no abstract was available in the database, the abstract of the printed article was used. The selected articles were then obtained in full text. If title and abstract did not provide sufficient information regarding the inclusion criteria, the full report was obtained as well. Again, disagreements were resolved by discussion.
Finally, the selection based on inclusion/exclusion criteria was made for the full text articles.
For this purpose Material and Methods, and Results of these studies were screened. This step was again carried out independently by 2 readers. Disagreements were resolved by discussion.
Data extraction
The data were independently extracted by 2 reviewers using data extraction tables. Any disagreements were resolved by discussion aiming for consensus. For clinical studies, information on the following parameters was extracted: authors, year of publication, study design, number of patients, mean age of patients, follow-up period, applied dose of growth factor, carrier system, control group, type and dimension of defect, decrease in defect height/increase in bone height/width, newly formed bone, and new bone density. For all categories, obtained data for preclinical studies included: authors, year of publication, animal species, number of animals, follow-up period, applied dose of growth factor, carrier system, control group(s), type and dimension of defect, percentage of defect fill, bone-to-implant contact, regenerated bone area, regenerated bone height/width, bone mineral density, and radiopacity of regenerated bone area.
Results
Study characteristics
The 10 electronic searches identified a total of 132, 145, 482, 774, 594, 267, 16, 36, 433, and 755 titles for "PDGF humans", "PDGF animals", "BMP-2 humans", "BMP-2 animals", "PTH humans", "PTH animals", "GDF-5 humans", "GDF-5 animals", "BMP-7 humans", and "BMP-7 animals", respectively (for details refer to Fig. 1-10) . From assessing the titles, 2997 were excluded (inter-reader agreement k=0.87 ± 0.01). The resulting number of abstracts obtained was 43, 50, 95, 242, 36, 45, 3, 4, 30 , and 89 for "PDGF humans", "PDGF animals", "BMP-2 humans", "BMP-2 animals", "PTH humans", "PTH animals", "GDF-5 humans", "GDF-5 animals", "BMP-7 humans", and "BMP-7 animals", respectively. Screening these abstracts, 510 were excluded. Five, 16, 10, 54, 4, 8, 1, 4, 7, and 20, respectively , full text articles were obtained. Finally, 0, 9, 6, 45, 0, 4, 0, 1, 0, and 9 articles, respectively, met the inclusion criteria.
Exclusion of studies
The main reasons for excluding studies (n=19) after the full text was obtained were: an insufficient number of animals/patients, no control group (preclinical studies), and no reported or insufficient clinical, radiographic, or histological treatment outcomes (only descriptive presentation of results). One study (Cochran et al. 2000) was excluded, since it reported on data from an earlier publication (Boyne et al. 1997 ). An additional study (Terheyden et al. 2001) was excluded, since the data were congruent with another publication (Terheyden et al. 1999 ).
Included studies
The 74 studies that met the inclusion criteria are presented in Tables 1-6. Table 1 represents data for human studies using BMP-2. Tables 2-6 refer to preclinical studies for all growth factors (BMP-2, -7, GDF-5, PDGF, and PTH). For all growth factors other than BMP-2, no human studies were found to meet the inclusion criteria.
Human studies
Bone morphogenic protein-2 (BMP-2)
Six studies reporting on bone augmentation with BMP-2 were included in the analysis. Four studies were designed as randomized controlled clinical trials (RCT), and two as prospective cohort studies. A total number of 183 patients were treated with growth factors for local intraoral bone regeneration. The mean age of the patients was 52 years. The mean follow-up period was 4.3 (4 to 6) months. BMP-2 was always locally administered. The applied dose of BMP-2 ranged from 0.5 to 1.75 mg/mL, or 0.12 to 3.4 mg/patient, respectively. Two different carrier systems were used for the application of BMP-2. Five studies used an absorbable collagen sponge (ACS), whereas in one study the growth factor was applied in a demineralized bovine bone matrix (DBBM) (Jung et al. 2003) .
The type of local bone augmentation encompassed sinus floor augmentations (Boyne et al. 1997 , Boyne et al. 2005 , preservations of extraction socket (Howell et al. 1997 , Bianchi et al. 2004 Fiorellini et al. 2005) , augmentation of localized ridge defects (Howell et al. 1997) , and lateral ridge augmentation in combination with simultaneous implant placement (Jung et al. 2003) . Due to the heterogeneity of the studies (various indications, RCT or cohort) no meta-analysis of the outcomes was performed.
Treatment outcomes
Patient-based treatment outcomes on local bone augmentation retrieved from 6 included studies are presented in Table 1 .
(1) Bone height increase / Defect size decrease An increase in bone height ranging from 6.8 to 10.2mm (for sinuslift procedures, lateral ridge augmentations), and a change in bone height between -2.1 and 2.4 mm (for ridge preservations/extraction socket augmentations) were reported for sites treated with BMP-2. Four RCTs included at least one control group without the application of the growth factors (Jung et al. 2003 , Bianchi et al. 2004 Boyne et al. 2005; Fiorellini et al. 2005) . In one of these studies, data for bone height were presented, and the average gain in bone height was 11.3 mm for control sites, and 9.5 mm for test sites with BMP-2, respectively (Boyne et al. 2005) . Two studies reported on the treatment outcome measured as a decrease in defects size (Jung et al. 2003) or change in bone height (Fiorellini et al. 2005) . The effect of the growth factor varied and was different in each study. The dose of the applied factor seemed to have an impact on the treatment outcome, with higher local bone regeneration for higher BMP-2 doses (Bianchi et al. 1994; Howell et al. 1997; Boyne et al. 2005) , and less decrease in bone height at extraction socket sites (Fiorellini et al. 2005) . Compared to controls without growth factors, the effect of BMP-2 revealed substantial variability. Data from one study showed no statistically significant effects of BMP-2 on the treatment outcome in a lower dose, but a statistically significant positive effect in a higher dose (Fiorellini et al. 2005) . Another study found no statistically significant differences to the control group regarding the increase in ridge height, and even less ridge width with the use of BMP-2 (Boyne et al. 2005) . Only one RCT reported a positive effect compared to the control group, when the factor was applied for lateral ridge augmentation (Jung et al. 2003) .
(2) New bone formation
Three studies reported on new bone formation either as a percentage of the original defect (Jung et al. 2003) , as gain in bone volume (Bianchi et al. 2004 ), or as new bone density (Boyne et al. 2005 ). The effect of applying BMP-2 varied between statistically significant less new bone density with the factor (Bianchi et al. 2004) , statistically not significantly more bone formation in a lower dose (Boyne et al. 2005) , and statistically significantly more newly formed bone with a higher dose (Boyne et al. 2005) compared to control groups. One study reported a positive but not statistically significant effect of BMP-2 regarding the amount of newly formed bone (37 ± 11.2%) compared to the control group (30 ± 8.9%) (Jung et al. 2003) . However, statistically significantly more mature lamellar bone (76 ± 14.4% vs. 56 ± 18.3%) and statistically significantly more bone to graft contact (57 ± 16.2% vs. 30 ± 22.6%) was detected at the BMP-2 treated sites compared to the sites grafted without BMP-2.
Animal studies
Since a large heterogeneity exists within the included animal studies, the obtained data for all growth factors were not further analyzed and, hence, presented in a descriptive manner in Tables 2-6. Table 2 represents data retrieved from animal studies using BMP-2. A total number of 45 preclinical studies fulfilled the inclusion criteria. The following animal species were used: rats, rabbits, goats, mini-pigs, and dogs. The type of defect prepared and treated for local bone augmentation encompassed critical-size defects in the skull, mandibular defects, peri-implant defects, alveolar ridge augmentation, sinus lift procedures, extraction sockets, vertical ridge augmentation, alveolar periodontal defects for vertical ridge augmentation.
Bone morphogenic protein-2 (BMP-2)
Treatment outcomes
Due to the large heterogeneity concerning animals species, type of defects, applied dose of BMP-2, carrier system, observation periods, treatment outcomes of these preclinical studies cannot be compared. The effect of the applied growth factor varies from study to study and even within the same study from time-point to time-point. In 43 of the 45 included studies at least at one time-point and compared to at least one control group a positive effect or even statistically significant differences were found in favor of using BMP-2. Only 2 studies were not able to show any positive effect using BMP-2 for local bone augmentation (Brandao et al. 2004; Liu et al. 2007 ).
Bone morphogenic protein-7 (BMP-7)
Table 3 represents data obtained from animal studies using BMP-7. Eight studies met the inclusion criteria. Rats, rabbits, baboons, and chimpazees were chosen as animal models. The type of defects encompassed extraction sockets, calvarial defects, and sinus augmentation procedures with or without simultaneous implant placement.
Treatment outcomes
As for BMP-2, these studies on BMP-7 could not be compared with each other due to substantial heterogeneity. In 6 studies (Ripamonti et al. 1996; McAllister et al. 1998; Terheyden et al. 1999; Ripamonti et al. 2001; Liu et al. 2006; Mhawi et al. 2007 ), a positive effect was associated with the use of BMP-7 at least at one time-point and compared to at least one control group. Only 2 studies failed to show any positive effect of BMP-7 (Margolin et al. 1998; Springer et al. 2005) . Table 4 shows data obtained from one included study (Poehling et al. 2005) .
Growth/differentiation factor-5 (GDF-5)
Treatment outcomes
500µg of rhGDF-5 were applied using ß-tricalciumphosphate (ß-TCP) as a carrier material in critical size defects in the Sprague-Dawley rats. The treatment outcome after an observation period of 6 weeks revealed statistically significant more bone formation compared to the control groups (ß-TCP, bovine bone mineral (BBM), BBM plus collagen, BBM plus a synthetic peptide, and a shamoperated site).
Platelet-derived growth factor (PDGF)
Nine studies met the inclusion criteria (Table 5 ). The surgeries were performed in rats, rabbits, and dogs. Calvarial defects, denuded mandibular ramus', peri-implant defects, vertical bone regeneration in the mandible, and local bone regeneration around immediate implants in fresh extraction sockets were used as models.
Treatment outcomes
Eight studies reported treatment outcomes on newly formed bone. Statistically significantly more bone volume was observed in 4 studies (Vikjar et al. 1997; Lee et al. 2000; Meraw et al. 2000; Lee et al. 2001) . The remaining 4 studies reported no significant differences when using rhPDGF as growth factor, or even significantly less bone formation compared to the controls (Marden et al. 1993; Stefani et al. 2000; Lioubavina-Hack et al. 2005a&b) . Data regarding the bone-to-implant contact (BIC) were obtained from 2 studies (Meraw et al. 2000; Stefani et al. 2001) . In one study (Meraw et al. 2000) , the BIC was significantly higher at the test sites at 12 weeks. These data were different from the second study (Stefani et al. 2000) that showed a statistically significantly greater BIC at 3 weeks, but not for the later observation periods at 8 and 12 weeks. Only clinical treatment outcomes were reported in one study (Simion et al. 2006 ), Compared to the control group without PDGF (25%), more sites healed uneventfully using the growth factor (75%). No data on bone regeneration were reported in that study.
Parathyroid hormone (PTH)
Four studies met the inclusion criteria (Table 6 ). Two studies were performed in rats ( 
Treatment outcomes
All 4 studies reported different treatment outcomes and hence, could not be compared.
Compared to the controls, statistically significantly more new bone volume was observed for the tested PTH independently of the animal model.
Discussion
The present systematic review assessed the potential of BMP-2, BMP-7, GDF-5, PDGF, and PTH for intraoral bone augmentation. In humans, only 6 studies investigating BMP-2 met the inclusion criteria and demonstrated generally a positive, but heterogeneous effect on local bone augmentation. In animals, a total of 67 included studies reported about BMP-2, BMP-7, GDF-5, PDGF, and PTH in various animal models and with various protocols. Although inconsistent results have been reported, the majority of the studies demonstrated statistically significantly more bone formation compared to control treatments without growth factors.
Different growth factors are now on the way to enter clinical practice in dentistry. Hence, it is of utmost importance to systematically assess the effect of the growth factors on the healing of intraoral bone defects. The present electronic search identified a total of 3634 titles for the application of growth factors. However, only 4 randomized controlled clinical trials (RCTs) on BMP-2 were available for analysis. No human RCT for BMP-7, GDF-5, PDGF and PTH could be found. This in turn means, that the clinical documentation of the effect of growth factors for the application in the oral cavity is sparse. Hence, there is a need for further randomized controlled clinical trials using growth factors for intraoral bone augmentation in well defined clinical indications.
Bone morphogenic protein-2 (BMP-2)
Out of the six included human studies, five applied BMP-2 in an absorbable collagen sponge (ACS). All of these studies have investigated BMP-2 in bone defects, which are considered to be self-containing (i.e. sinus floor and extraction sockets). While it is recognized that collagen is one of the best researched carrier material, different animal studies have documented inadequate bone regeneration when collagen is used alone as a bone graft substitute (Barboza et al. 2000; Howell et al 1997) . Increased regeneration volume has been shown when collagen was combined with grafting materials (Miranda et al. 2005; Arosarena & Collins et al. 2005a ). Only one clinical study has tested BMP-2 applied with grafting material (demineralized bovine bone matrix) for lateral bone augmentation (Jung et al. 2003) . There is a lack of clinical data comparing the use of grafting materials over the use of collagen as carrier material for BMP-2 in non self-containing defects.
Besides the carrier material the dosage seems also to play an important role for the successful application of BMP-2. Three clinical studies have investigated two different doses for BMP-2 (Bianchi et al. 2004; Boyne et al. 2005; Fiorellini et al. 2005) . It was demonstrated that the higher dosage reveals better results. However, the dosage applied in these clinical studies are several orders of magnitude higher than naturally occurring BMP-2 concentrations (Urist et al. 1983) . In order to overcome some of these difficulties a variety of preclinical studies are testing new optimized carrier systems to decrease the dosage of BMP-2 (Jung et al. 2008) .
It is concluded from the present literature that BMP-2 has been extensively tested in preclinical models revealing generally positive effects on local bone regeneration. Future studies should aim for randomized controlled clinical trials to treat challenging intraoral bone defects.
Bone morphogenic protein-7 (BMP-7, OP-1)
No clinical study was found using BMP-7 for intraoral local bone regeneration. The majority of the animal studies have used collagen as carrier material. Only two studies have used grafting materials as carrier system (Ripamonti et al. 2001; Terheyden et al. 1999 ).
Five out of 8 included animal studies reported about the percentage of newly formed bone evaluated by histomorphometric measurements (Margolin et al. 1998; Ripamonti et al. 1996; McAllister et al. 1998; Ripamonti et al. 2001; Mhawi et al. 2007 ). Only one study in chimpanzee could not show a statistical significant difference compared to the control treatments without BMP-7 (Margolin et al. 1998) . The remaining studies revealed statistically significant more newly formed bone compare the to control sites. However, in two studies only the higher dosage was able to increase the amount of newly formed bone significantly (McAllister et al. 1998; Ripamonti et al. 2001 ).
It can be concluded that BMP-7 applied by collagen or grafting materials was able to stimulate bone regeneration in different animal models. Future research should be directed towards randomized controlled clinical trials.
Growth/differentiation factor-5 (GDF-5)
Very little data is available for the use of GDF-5 in local bone augmentation. Only one study performed in rats was included in the present review (Poehling et al. 2005) . It was demonstrated that GDF-5 significantly increased the amount of newly formed bone in critical sized calvarial defects compared to augmenting with standard grafting techniques (e.g. demineralized bovine bone matrix, DBBM). Wound healing in the control groups was mainly characterized by the formation of loose fibroconnective tissue and only limited bone formation at the defect margins. These observations are not in agreement to other animal studies using DBBM for bone regeneration (Thaller et al. 1994; Donos et al. 2004 ).
Due to the fact that only one study with one animal model, one concentration, and one time point investigated GDF-5 for intraoral bone augmentation no conclusions can be drawn. Further preclinical research is needed in order to understand the effect of GDF-5.
Platelet derived growth factor (PDGF)
Nearly fifty percent of all included animal studies investigating PDGF for intraoral bone augmentation were not able to show a significant effect compared to control treatments without PDGF. These limited results are in contrast to a recent human pilot study using PDGF for threedimensional ridge augmentation (Simion et al. 2007 ). It was demonstrated in 2 patients, that rhPDGF-BB combined with a deproteinized bovine bone block without the placement of a barrier membrane, had the potential to regenerate significant amounts of new bone in severe mandibular ridge defects.
In the past, PDGF has mainly been tested for the treatment of periodontal defects (Lynch et al. 1991; Nevins et al. 2005) . In a 24-month prospective randomized controlled clinical trial the combination of rhPDGF-BB and beta-tricalcium phosphate (TCP) was evaluated in the treatment of periodontal defects . They showed a significant gain in clinical attachment level and significantly greater radiographic linear bone gain and percent defect fill compared to sites that received bone substitute with buffer. The controversial results using PDGF for either periodontal defects or bone defects might be explained by the fact that PDGF has been shown to be mitogenic and chemotactic for periodontal ligament cells but not osteoinductive (Lynch et al. 1989; Lynch et al. 1991 ). Hence, the stimulating effect on osteoblasts might be limited.
Based on the data of 9 animal studies, it can be concluded that PDGF has an unpredictable and limited effect on intraoral bone regeneration. 
Parathyroid hormone (PTH)
A limited number of studies investigated the use of peptide fragment of the parathyroid hormone (PTH 1-34 ) for local bone regeneration (Andreassen & Cacciafesta 2004; Jung et al. 2007a&b ). While PTH has been shown to have a substantial beneficial effect in the systemic treatment of osteoporosis, its use for the treatment of local bone defects is relatively new. The 4 included studies revealed all a statistically significant benefit compared to control treatments without using PTH. Two of the studies have administrated PTH by intermittent subcutaneous injections (Andreassen & Cacciafesta 2004; Skriptiz et al. 2000) and 2 by local application of the PTH peptide (Jung et al. 2007a&b ). Replacement of intermittent systemic injections of PTH by local release of the peptide would be beneficial regarding dosage and patient comfort. Newly developed carrier systems, like polyethylene-glycol (PEG), have been designed for local presentation of growth factors and peptides (Lutolf et al. 2003; Jung et al. 2007b) . It was demonstrated that the PEG carrier system was able to control the release of growth factors (Lutolf et al. 2003) . This might be especially important for the local administration of PTH for the treatment of intraoral bone defects.
It can be concluded that a 34 amino acid peptide of the PTH is an interesting candidate for the treatment of local bone defects. However, future research is mandatory in order to better understand the way of action of the PTH for the therapy of intraoral bone defects.
Conclusion
From the analysis of this systematic search of the literature it is evident that BMP-2, BMP-7 (OP-1), GDF-5, PDGF and PTH may stimulate local bone augmentation to various amounts as documented by preclinical animal studies. However, only the application of BMP-2 has been studied in clinical trials. Owing to the fact that various indications for local intraoral bone augmentation could benefit from the use of BMP-2 the performances of RCTs in well-defined indications is a prerequisite for the routine recommendation of BMP-2 in bone augmentation procedures. Moreover, it is obvious that growth factors should only be applied to challenging intraoral bone defects. Cochran 2000 recall and implant placement in augmented bone of previous study (Boyne et al. 1997) 
